Open access peer-reviewed Edited Volume

Bladder Cancer

Sivapatham Sundaresan

SRM Institute of Science and Technology

Researcher in cancer and nutrition. Associate Professor of Medical Research, Annual Member of ACBI, Teacher, and Researcher in SRM MCH and RC, SRM IST.


Muscle Invasive Cystectomy Therapy and Drugs Combinational Therapy Immune Checkpoint Inhibitors miRNA Microsatellite Alterations Methylation Post-translational Modification Bladder Cancer Nutrition Prevention Causes

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

This book will be enabled to bring the scope of the role of drug targets, epigenetics, nutrition emerging biomarkers, miRNA, and diagnostic approaches for Bladder cancer. The book will feature an understanding of the molecular biology and genetics of bladder cancer - evolved the way localized and advanced disease is diagnosed and treated globally. This book will provide the scope including evolving therapeutic options such as immunotherapy with checkpoint inhibition and targeted therapies for muscle-invasive and advanced disease. Insights in Non–muscle-invasive tumors treated with endoscopic resection and adjuvant intravesical therapy, depending on the risk classification are included. A diagnostic utility like enhanced cystoscopy including technology used to improve the detection of tumors and can reduce the risk of recurrence will also be chaptered. Key RNA markers that may assist in the diagnosis of BC and recent advances in Chemotherapy for bladder cancer necessary to expose and reflect on future perspectives are also the scope of the study.

Publishing process

Book initiated and editor appointed

Date completed: March 24th 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: May 27th 2022

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: July 26th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 14th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 13th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Sivapatham Sundaresan

SRM Institute of Science and Technology

Dr. S. Sundaresan has been working in the field of cancer chemoprevention, cancer immunotherapy, and tumor marker detection. Translational research (TR) has been described as translating research into medical practice and translating science into better healthcare. Translational research on tumor biomarkers has successfully promoted the development of tumor treatment and has brought new hope for cancer patients. It is important to direct cancer research on diagnosis and treatment toward applying fundamental research findings to the clinic as soon as possible, and applying novel tumor molecular markers to early diagnosis, targeted therapy, and individualized treatment. Focused medical treatment should be given through the analysis of new tumor biomarkers and appropriate treatments. Dr. S. Sundaresan has been working with oral cancer and cancer biomarkers. There are newer molecular markers that are of clinical significance and they need to be studied in various populations. The administration of indoles and triterpenes for preventive and curative effects was studied in laboratory animals. Dr. S. Sundaresan’s research study also demonstrates interferon beta synergistically works with chemotherapeutic drug cisplatin for liver, breast, and cervix cancer cells.

View profile

Book chapters authored 2

Books edited 2

Introducing your Author Service Manager

Mrs. Blanka Gugic

As an Author Service Manager, my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in